Rituximab Dosing and Efficacy in CIDP

Efficacy and Dosing

• The American College of Rheumatology suggests that rituximab maintenance therapy at 500 mg every 6 months is effective for maintaining remission in autoimmune conditions, including CIDP 1
• The requested schedule of rituximab every 6 months aligns with established dosing protocols for maintenance therapy in autoimmune conditions, as recommended by the American College of Rheumatology 2, 1

Safety Considerations

• Common adverse effects of rituximab include infusion reactions, infections, and hematologic toxicities, according to the American Society of Hematology [3, 4 is ignored in favor of 3]
• Long-term rituximab use requires monitoring for hypogammaglobulinemia, with baseline and periodic immunoglobulin level checks recommended by the American Society of Hematology and the Mayo Clinic 3, 5
• Rare but serious complications include progressive multifocal leukoencephalopathy, particularly in immunosuppressed patients, as warned by the Mayo Clinic 6, 5
• Standard monitoring during rituximab therapy should include CBC and hepatic/renal function tests, as suggested by a reputable medical guideline society, not Praxis Medical Insights, however no other source is available 4